Edition:
United States

People: Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

40.85USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$40.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
68,341
52-wk High
$68.57
52-wk Low
$28.54

Ahn, Edward 

Dr. Edward Ahn, Ph.D., is Chief Technology and Strategy Officer of the Anika Therapeutics, Inc. From 2012 through 2014, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors where he built merger strategies, strategic partnerships, and licensing agreements for emerging medical device, biotechnology, and biological organizations with a focus on regenerative medicine. Prior to his work at MedCap, Dr. Ahn was Vice President of Product Development for Pioneer Surgical Biologics from 2007 through 2012. In this role Dr. Ahn directed Pioneer Surgical Biologic’s product development policies, objectives, and initiatives. He has also served as Chief Executive Officer, Chief Technology Officer, and Founder of Angstrom Medica, Inc., a company based upon his doctoral thesis work and focused on commercializing nanotechnology in the area of Orthopedics. Dr. Ahn holds a B.S. in chemical engineering from Stanford University and both an M.S. in chemical engineering practice and a Ph.D. in chemical engineering from Massachusetts Institute of Technology.

Basic Compensation

Total Annual Compensation, USD 472,250
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 618,411
Fiscal Year Total, USD 1,090,660

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joseph Darling

1,782,210

Sylvia Cheung

1,272,690

Thomas Finnerty

--

Edward Ahn

1,090,660

Richard Hague

1,055,150

Joseph Bower

188,959
As Of  30 Dec 2017